The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
This is a descriptive, cross-sectional clinical study including patients with histologically and/or biologically confirmed prostate cancer who are being followed in the participating centers. This study planned to enroll 500 patients. Data will be collected from medical records and structured patient interviews (≈30 minutes). A standardized electronic case report form (eCRF) will be used to ensure completeness and reliability of the data. The variables studied will include sociodemographic data, medical history, clinical and biological characteristics of the disease, diagnostic examinations performed, and the therapeutic strategies implemented. All information will be anonymized and used exclusively for research purposes.
Study Type
OBSERVATIONAL
Enrollment
2,000
CAC Adrar - Oncology Department
Adrar, Algeria, Algeria
NOT_YET_RECRUITINGCAC Adrar - Radiotherapy Department
Adrar, Algeria, Algeria
NOT_YET_RECRUITINGCAC BLIDA - Oncology Department
Algiers, Algeria, Algeria
RECRUITINGCentre Pierre et Marie Curie - Oncology Department
Algiers, Algeria, Algeria
RECRUITINGCentre Pierre et Marie Curie - Radiology Department
Algiers, Algeria, Algeria
RECRUITINGCHU Bab El Oued
Algiers, Algeria, Algeria
RECRUITINGCHU Béni Messous - Oncology Departement
Algiers, Algeria, Algeria
RECRUITINGEPH ROUIBA - Oncology Department
Algiers, Algeria, Algeria
RECRUITINGCAC Annaba - Oncology Departement
Annaba, Algeria, Algeria
RECRUITINGCAC Annaba - Radiotherapy Department
Annaba, Algeria, Algeria
RECRUITING...and 14 more locations
Socio-demographic characteristics of patients with prostate cancer in Algeria
Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level.
Time frame: At Baseline ( Initial visit )
Personal and family history of cancer
Frequency (%) of patients with personal and family history of cancer.
Time frame: At Baseline (Initial Visit)
Environmental and occupational exposures
Frequency (%) of patients with environmental or occupational exposures.
Time frame: At Baseline (Initial visit)
Smoking history
Frequency (%) of patients according to smoking status (current, former, never).
Time frame: At Baseline (Initial visit)
Alcohol consumption
Frequency (%) of patients according to alcohol consumption (yes/no).
Time frame: At Baseline (Initial visit)
Initial symptoms and circumstances of diagnosis
Frequency (%) of patients according to type of initial symptoms and circumstances of diagnosis.
Time frame: At Baseline (Initial visit)
International Prostate Symptom Score (IPSS)
Distribution of patients according to the International Prostate Symptom Score (IPSS) at baseline. The IPSS is a validated questionnaire assessing the severity of lower urinary tract symptoms, with a total score ranging from 0 to 35, where higher scores indicate more severe (worse) symptoms.
Time frame: At Baseline (Initial visit)
Evolutionary status of patients
Frequency (%) of patients according to disease status (in remission or with disease progression).
Time frame: At Baseline (Initial visit)
Diagnosis by PSA testing
% of patients diagnosed by PSA testing.
Time frame: At Baseline (Initial visit)
Diagnosis by imaging
% of patients diagnosed by imaging.
Time frame: At Baseline (Initial visit)
Diagnosis by biopsy
% of patients diagnosed by biopsy.
Time frame: At Baseline (Initial visit)
Time from symptom onset to first medical consultation
Median time (in days) between onset of first symptoms and first medical consultation.
Time frame: At Baseline (Initial visit)
Time from first consultation to confirmed diagnosis
Median time (in days) between first medical consultation and confirmed diagnosis.
Time frame: At Baseline (Initial visit)
Patients discussed in multidisciplinary team meetings
% of patients discussed in tumor boards / multidisciplinary team meetings.
Time frame: At Baseline (Initial visit)
Initial treatment: Surgery
% of patients receiving surgery as initial treatment.
Time frame: At Baseline (Initial visit)
Initial treatment: Radiotherapy
% of patients receiving radiotherapy as initial treatment.
Time frame: At Baseline (Initial visit)
Initial treatment: Hormone therapy
% of patients receiving hormone therapy as initial treatment.
Time frame: At Baseline (Initial visit)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Initial treatment: Active surveillance
% of patients under active surveillance as initial management.
Time frame: At Baseline (Initial visit)
Time from diagnosis to treatment initiation
Median time (in days) between diagnosis and treatment initiation.
Time frame: At Baseline (Initial visit)
Specialty of physician initiating treatment
Medical specialty of the physician initiating treatment (urologist, oncologist, etc.).
Time frame: At Baseline (Initial visit)
Adverse events
Frequency of adverse events by system/organ class and distribution according to severity grades (CTCAE grades 1 to 5).
Time frame: At Baseline (Initial visit)